BioWorld Asia

Dec. 22, 2010

EpiTherapeutics, Abbott in Epigenetics Oncology Deal

EpiTherapeutics ApS, which is developing cancer drugs based on epigenetics targets, entered its first drug discovery pact, with Abbott, of Abbott Park, Ill. (BioWorld International) Read More

Xention Spins Out Provesica to Advance Bladder Drug

Genomics of Lung Cancer Yields a New Drug Target

NovImmune Tops Off Cash with $20M for Antibody Trials

Two Biotechs Merge to Form PsiOxus Therapeutics

Proximagen Picks up GSK's Discarded CNS Programs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 22, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...